Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
latanoprost + dorzolamide (Chong Kun Dang Holdings)
- Development stage
- Phase 2
- Lead developer
- Chong Kun Dang Pharmaceutical
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
CKD-351 is a fixed-dose combination drug consisting of latanoprost and dorzolamide. It is being developed by Chong Kun Dang for the treatment of primary open-angle glaucoma and ocular hypertension. The drug acts as an agonist at the prostanoid FP receptor (PTGFR), which is targeted by latanoprost to increase aqueous humor outflow and reduce intraocular pressure. Dorzolamide inhibits carbonic anhydrase II in the ciliary processes of the eye, decreasing aqueous humor secretion. This dual mechanism aims to provide enhanced intraocular pressure reduction for patients with glaucoma or ocular hypertension[1][7].
- Brand names
- Eyedorz-L
- Other names
- CKD-351CKD351CKD 351latanoprost + dorzolamide
02
Targets
CA2 (Carbonic Anhydrase 2)PTGFR (Prostaglandin F2 alpha receptor)
Beyond the preview
Go deeper on latanoprost + dorzolamide (Chong Kun Dang Holdings).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on latanoprost + dorzolamide (Chong Kun Dang Holdings).